Descripción

Lagevrio – Oral Antiviral for COVID-19 (Rx)

Lagevrio (molnupiravir) is an oral antiviral medication used for the treatment of mild to moderate COVID-19 in adults who are at high risk of progressing to severe disease. It is a nucleoside analog antiviral that works by introducing errors into the viral RNA during replication, a process known as viral “error catastrophe”, which reduces the ability of the virus to multiply.

buy Lagevrio with no prescription

We sell over-the-counter Lagevrio medicine; buy medicines with no prescription
entrega rápida, discreta y confiable
pago rápido y seguro
Comprar discretamente sin dejar rastro

It is not intended for hospitalized patients requiring oxygen support and is most effective when started early in the course of infection.

Key Details

• Active Ingredient: Molnupiravir
• Brand Name: Lagevrio
• Drug Class: Antiviral (ribonucleoside analog)
• Indication: Mild–moderate COVID-19 in high-risk adults
• Mechanism of Action: Induces viral RNA replication errors → inhibits SARS-CoV-2 replication
• Route: Oral capsule
• Prescription Status: Prescription-only medicine

Especificaciones

• Dosage Form: Capsules
• Common Strength: 200 mg capsules
• Standard Dose: 800 mg (4 capsules) twice daily
• Treatment Duration: 5 days
• Administration: Oral, with or without food
• Onset of Action: Works during early viral replication phase
• Metabolism: Hydrolyzed to active form (N-hydroxycytidine)
• Excretion: Primarily renal
• Storage: Room temperature

Dosage & Administration

• Take 4 capsules twice daily for 5 days
• Must be started as soon as possible after diagnosis and within early symptom onset (typically within 5 days)
• Complete the full course even if symptoms improve
• Capsules should be swallowed whole

Compatibility / Suitable Use

• Adults with mild to moderate COVID-19
• Patients at high risk of progression (e.g., older age, chronic disease, immunocompromised)
• Outpatient or early-stage treatment setting
• Not used as a substitute for vaccination

Adverse Effects

• Common: Diarrhea, nausea, dizziness, headache
• Rare: Allergic reactions
• Generally considered well tolerated in short-course use

Why Choose Lagevrio?

Lagevrio provides a simple oral 5-day antiviral regimen for early treatment of COVID-19 in high-risk patients. Its mechanism targets viral replication directly, helping reduce the risk of severe disease when used promptly after symptom onset.